FatiAbGen International is the Swiss subsidiary of FatiAbGen Inc., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.
Products, services, technology
We are currently developing antibody-drug conjugates to target high unmet need oncology indications.
We also have pre-clinical, best in class antibodies to address allergy/asthma indications.
Cooperation possibilities
We are always looking for partners to accelerate and de-risk the development of our oncology and immunology antibody-based therapeutics.
Following an over-subscribed Series A in 2024-2025, we are also raising Series B and as such looking for investors in our company.
- https://www.fatiabgen.com
- Send an email
- Alexandre Joyeux
Some insights
FatiAbGen aims to discover new therapeutics for oncology and immunology indications with the highest unmet needs.
FatiAbGen is a unique place to work, with strong core values of collaboration and integrity. We also focus on indications with the highest unmet needs with the hope to make a significant difference for patients, their carers and health care systems.
Our team's core strengths are in antibody engineering, pre-clinical development, commercial evaluation/market access and partnerships. In the future, we look forward to incorporate clinical development, legal/IP and out-licensing/M&A expertise.
We look forward to partnering with companies in the Swiss biotech ecosystem to advance our pipeline of best-in-class antibodies to address high unmet need indications in oncology and immunology.
Investors, innovators in the antibody/ADC/Bi-specific fields, CDMOs with unique value propositions, IP specialists with global expertise